نتائج البحث

Haptoglobin phenotype and levels in type 2 diabetes and effects of fenofibrate.

• Authors : Januszewski, Andrzej S.^1,2,3 (AUTHOR) ; Young, Hayden K.⁴ (AUTHOR); Ong, Kwok‐Leung¹ (AUTHOR)

• Source: Journal of Diabetes Investigation. Nov2024, Vol. 15 Issue 11, p1663-1668. 6p.

تفاصيل العنوان

Investigating the Influence of Processing Conditions on Dissolution and Physical Stability of Solid Dispersions with Fenofibrate and Mesoporous Silica.

• Authors : Baumgartner, Ana¹ (AUTHOR) ; Dobaj, Nina¹ (AUTHOR); Planinšek, Odon¹ (AUTHOR)

• Source: Pharmaceutics. May2024, Vol. 16 Issue 5, p575. 23p.

تفاصيل العنوان

Fenofibrate Recognition and Gq Protein Coupling Mechanisms of the Human Cannabinoid Receptor CB1.

• Authors : Wang, Tianxin^1,2 (AUTHOR); Tang, Wenqin^3,4,5 (AUTHOR); Zhao, Ziyi^3,4,5 (AUTHOR)

• Source: Advanced Science. 4/10/2024, Vol. 11 Issue 14, p1-8. 8p.

تفاصيل العنوان

Pharmacological Preconditioning with Fenofibrate in Cardiomyocyte Cultures of Neonatal Rats Subjected to Hypoxia/Reoxygenation, High Glucose, and Their Combination.

• Authors : Oidor-Chan VH; Department of Biotechnology, Autonomous Metropolitan University, Iztapalapa Campus, Av. Ferrocarril de San Rafael Atlixco 186, Col. Leyes de Reforma 1ª. Sección, Alcaldía Iztapalapa, Mexico City 09310, Mexico.; Sánchez-López A

Subjects: Myocytes, Cardiac*/Myocytes, Cardiac*/Myocytes, Cardiac*/drug effects ; Myocytes, Cardiac*/Myocytes, Cardiac*/Myocytes, Cardiac*/metabolism ; Glucose*/Glucose*/Glucose*/metabolism

• Source: International journal of molecular sciences [Int J Mol Sci] 2024 Oct 23; Vol. 25 (21). Date of Electronic Publication: 2024 Oct 23.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067

تفاصيل العنوان

Study Design and Protocol for a Randomized Controlled Trial to Assess Long-Term Efficacy and Safety of a Triple Combination of Ezetimibe, Fenofibrate, and Moderate-Intensity Statin in Patients with Type 2 Diabetes and Modifiable Cardiovascular Risk Factors (ENSEMBLE).

• Authors : Kim NH; Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.; Lee J

Subjects: Cardiovascular Diseases*/Cardiovascular Diseases*/Cardiovascular Diseases*/prevention & control ; Cardiovascular Diseases*/Cardiovascular Diseases*/Cardiovascular Diseases*/drug therapy ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy

• Source: Endocrinology and metabolism (Seoul, Korea) [Endocrinol Metab (Seoul)] 2024 Oct; Vol. 39 (5), pp. 722-731. Date of Electronic Publication: 2024 Aug 22.Publisher: Korean Endocrine Society Country of Publication: Korea (South) NLM ID: 101554139 Publication Model: Print-Electronic Cited Medium: Internet

تفاصيل العنوان

Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma

• Authors : Lindsay Ferguson, MD, Principal Investigator

• Source: Window of Opportunity Trial of Fenofibrate in Patients With High-grade Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma

تفاصيل العنوان

High-Dose Fenofibrate Stimulates Multiple Cellular Stress Pathways in the Kidney of Old Rats.

• Authors : Wrońska, Agata¹ (AUTHOR) ; Kieżun, Jacek² (AUTHOR) ; Kmieć, Zbigniew¹ (AUTHOR)

Subjects: *FENOFIBRATE; *KIDNEY cortex; *FATTY acid oxidation

• Source: International Journal of Molecular Sciences. Mar2024, Vol. 25 Issue 5, p3038. 18p.

تفاصيل العنوان

Cardiometabolic benefits of fenofibrate in heart failure related to obesity and diabetes.

• Authors : Park J; Department of Biomedical Science and Engineering, Gwangju Institute of Science and Technology, Gwangju, Korea.; Song H

Subjects: Fenofibrate*/Fenofibrate*/Fenofibrate*/therapeutic use ; Fenofibrate*/Fenofibrate*/Fenofibrate*/pharmacology ; Obesity*/Obesity*/Obesity*/drug therapy

• Source: Cardiovascular diabetology [Cardiovasc Diabetol] 2024 Sep 16; Vol. 23 (1), pp. 343. Date of Electronic Publication: 2024 Sep 16.Publisher: BioMed Central Country of Publication: England NLM ID: 101147637 Publication Model: Electronic Cited Medium: Internet ISSN: 1475-2840

تفاصيل العنوان

Fenofibrate to prevent amputation and reduce vascular complications in patients with diabetes: FENO-PREVENT.

• Authors : Ku EJ; Department of Internal Medicine, Seoul National University Hospital Healthcare System Gangnam Center, Seoul, South Korea.; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea.

Subjects: Fenofibrate*/Fenofibrate*/Fenofibrate*/therapeutic use ; Fenofibrate*/Fenofibrate*/Fenofibrate*/adverse effects ; Amputation, Surgical*/Amputation, Surgical*/Amputation, Surgical*/adverse effects

• Source: Cardiovascular diabetology [Cardiovasc Diabetol] 2024 Sep 03; Vol. 23 (1), pp. 329. Date of Electronic Publication: 2024 Sep 03.Publisher: BioMed Central Country of Publication: England NLM ID: 101147637 Publication Model: Electronic Cited Medium: Internet ISSN: 1475-2840

تفاصيل العنوان

A Pilot Study of Fenofibrate to Prevent Kidney Function Loss in Type 1 Diabetes (PERL-FENO)

• Authors : University of Michigan; University of Minnesota; Alessandro Doria, Senior Investigator and Professor of Medicine

• Source: A Pilot Study of Fenofibrate to Prevent Kidney Function Loss in Type 1 DiabetesDavis TM, Ting R, Best JD, Donoghoe MW, Drury PL, Sullivan DR, Jenkins AJ, O'Connell

تفاصيل العنوان